In this episode, we take a closer look at the VANISH2 study, a groundbreaking piece of research recently published in The New England Journal of Medicine. This study tackles a crucial question: should patients with ischemic cardiomyopathy and ventricular tachycardia start treatment with catheter ablation or antiarrhythmic drugs? We’ll break down the key findings, including how ablation seemed to outperform medication in reducing ICD shocks and improving survival rates. But what do these results mean for doctors and patients in real-life settings? Tune in as we explore the practical implications and discuss what might change in how we manage this serious heart condition.